# Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

> **NCT06766500** · PHASE1 · COMPLETED · sponsor: **Gedeon Richter Plc.** · enrollment: 64 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablets
- **DRUG:** Synjardy® 5 mg/850 mg film-coated tablets

## Key facts

- **NCT ID:** NCT06766500
- **Lead sponsor:** Gedeon Richter Plc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-20
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-02-28
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06766500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06766500, "Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06766500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*